Daplusiran

Daplusiran is a siRNA in JNJ-3989 (JNJ-73763989) . JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.

Product Specifications

CAS Number

[2202783-35-3]

UNSPSC

12352208

Target

HBV

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

[Daplusiran]

Molecular Formula

C492H650F12N163O310P43S7

Molecular Weight

15591.60

References & Citations

[1]Kakuda TN, Halabi A, Klein G, et al. Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment. J Clin Pharmacol. 2023;63 (6) :732-741.|[2]Li H, Niu X, Zhang Y, et al. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants. Clin Pharmacol Drug Dev. 2023;12 (2) :175-180.|[3]Gane E, Yuen MF, Kakuda TN, et al. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos (t) ide analogue in patients with chronic hepatitis B. Antivir Ther. 2022;27 (3) :13596535221093856.

Shipping Conditions

Room temperature

Scientific Category

Oligonucleotides

Clinical Information

Phase 2